within Pharmacolibrary.Drugs.ATC.C;

model C09CA02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.13,
    Cl             = 0.002033333333333333,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.013,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.009000000000000001,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C09CA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Eprosartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension (high blood pressure). It is approved for therapeutic use in lowering blood pressure and reducing the risk of cardiovascular events. Eprosartan is considered effective and is approved for use in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after a single oral administration.</p><h4>References</h4><ol><li><p>Bottorff, MB, &amp; Tenero, DM (1999). Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations. <i>Pharmacotherapy</i> 19(4 Pt 2) 73S–78S. DOI:<a href=&quot;https://doi.org/10.1592/phco.19.7.73s.30946&quot;>10.1592/phco.19.7.73s.30946</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10213525/&quot;>https://pubmed.ncbi.nlm.nih.gov/10213525</a></p></li><li><p>Tenero, DM, et al., &amp; Jorkasky, DK (1998). Effect of age and gender on the pharmacokinetics of eprosartan. <i>British journal of clinical pharmacology</i> 46(3) 267–270. DOI:<a href=&quot;https://doi.org/10.1046/j.1365-2125.1998.00778.x&quot;>10.1046/j.1365-2125.1998.00778.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9764969/&quot;>https://pubmed.ncbi.nlm.nih.gov/9764969</a></p></li><li><p>Blum, RA, et al., &amp; Tenero, DM (1999). A review of eprosartan pharmacokinetic and pharmacodynamic drug interaction studies. <i>Pharmacotherapy</i> 19(4 Pt 2) 79S–85S. DOI:<a href=&quot;https://doi.org/10.1592/phco.19.7.79s.30948&quot;>10.1592/phco.19.7.79s.30948</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10213526/&quot;>https://pubmed.ncbi.nlm.nih.gov/10213526</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C09CA02;
